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Abstract
Background
The target group for severe respiratory syncytial virus (RSV) disease prevention is infants
under 6 months of age. Vaccine boosting of antibody titres in pregnant mothers could pro-
tect these young infants from severe respiratory syncytial virus (RSV) associated disease.
Quantifying protective levels of RSV-specific maternal antibody at birth would inform vac-
cine development.
Methods
A case control study nested in a birth cohort (2002–07) was conducted in Kilifi, Kenya;
where 30 hospitalised cases of RSV-associated severe disease were matched to 60 con-
trols. Participants had a cord blood and 2 subsequent 3-monthly blood samples assayed for
RSV-specific neutralising antibody by the plaque reduction neutralisation test (PRNT). Two
sample paired t test and conditional logistic regression were used in analyses of log2PRNT
titres.
Results
The mean RSV log2PRNT titre at birth for cases and controls were not significantly different
(P = 0.4) and remained so on age-stratification. Cord blood PRNT titres showed consider-
able overlap between cases and controls. The odds of RSV disease decreased with
increase in log2PRNT cord blood titre. There was a 30% reduction in RSV disease per unit
increase in log2PRNT titre (<3months age group) but not significant (P = 0.3).
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Conclusions
From this study, there is no strong evidence of protection by maternal RSV specific antibod-
ies from severe RSV disease. Cord antibody levels show wide variation with considerable
overlap between cases and controls. It is likely that, there are additional factors to specific
PRNT antibody levels which determine susceptibility to severe RSV disease. In addition,
higher levels of neutralizing antibody beyond the normal range may be required for protec-
tion; which it is hoped can be achieved by a maternal RSV vaccine.
Introduction
Respiratory syncytial virus (RSV) is the most common viral cause of severe acute lower respi-
ratory infections among children aged less than 5 years [1–3]. Global estimates indicate that
RSV is present in 29% of all ALRI episodes[1] and responsible for approximately 66000–
199000 deaths of under 5 year old children worldwide, with majority (99%) of these deaths
occurring in developing countries[2].
A target group for RSV prevention is children under 6 months old who are highly suscepti-
ble to severe RSV associated disease[4]. Development of a vaccine to provide direct protection
to the infant has been impeded by historical failure of a formalin inactivated vaccine[5, 6] and
difficulties in designing an immunogenic live-attenuated vaccine that is well tolerated by the
young infant [7]. An alternative approach currently under consideration as a means of protect-
ing the vulnerable infant from RSV disease during the first few months of life is through vac-
cine boosting of maternal RSV-specific antibodies.
The concept of maternal vaccination has previously been used to prevent other viral infec-
tions such as poliovirus and influenza among infants or, in the case of rubella, in the foetus[8].
There is evidence that RSV specific maternal antibodies provide protection from severe RSV
disease [9–11]. In addition, monthly repeated prophylaxis with Palivizumab™ (a humanized
monoclonal IgG antibody) during the first RSV season among high risk infants reduced the
risk of RSV associated hospitalization by 55% [12]. Studies have also shown that there is effi-
cient transplacental transfer of RSV IgG antibodies during the third trimester of pregnancy,
implying that maternal immunization has the potential to benefit the young infant most sus-
ceptible to RSV infections[13, 14]. The concept of boosting of maternal antibody following
challenge is supported by significant population level rise in RSV-specific cord neutralising
antibody in synchrony with seasonal RSV [15–17].
Maternal RSV vaccines under development are based on the fusion F protein which is a tar-
get of neutralising antibodies and known to be highly conserved between variants. Immuniza-
tion with sub-unit RSV F protein has been shown to be safe and immunogenic in post-partum
women [8, 18]. The leading candidate, an F protein nanoparticle design [19], (http://sites.path.
org/vaccinedevelopment/respiratory-syncytial-virus-rsv/) is well tolerated and immunogenic
in healthy adults and 3rd trimester women (NCT02247726)) and is now undergoing phase 3
clinical trials (NCT02624947).
Despite these advances, the development of a maternal RSV vaccine is hindered by lack of
quantitative data on the level of maternal RSV specific neutralising antibodies at birth required
to provide protection against RSV disease among infants, and the duration over which this
protection would last. Here we report results of a case control study from a birth cohort in
Kilifi, a coastal part of Kenya, in which, the main objective was to quantify the level of RSV-
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specific maternal antibodies at birth that provide infant protection against severe disease. In
this context, we asked the following questions (i) Is there a quantifiable level of antibody that
provides protection in early life? (ii)Is the protective level absolute or is there a degree of pro-
tection against severe disease that varies with antibody level? (iii) Is there a differential rate of
decay of maternal antibodies in those who get RSV disease against those who do not?
Material and Methods
Study site, Population and Design
This study was conducted in Kilifi, the coastal part of Kenya [20]. The study was nested within
a previous birth cohort study. Between 1999 and 2007, Kenya Medical Research Institute-Well-
come Trust Research Programme (KEMRI-WTRP), conducted a Kilifi Birth Cohort (KBC)
study within the Kilifi Health and Demographic Surveillance System [20–22]. The KBC study
was an observational study where participants were followed for a two-year period with a cord
blood sample collected at birth and subsequent 3 monthly blood samples during follow ups.
Details of the birth cohort study are described elsewhere [16, 21, 22]. The KBC study partici-
pants had access to Kilifi County Hospital (KCH) previously referred to as Kilifi District Hos-
pital (KDH).
We conducted a case-control study using archived serum or plasma samples from partici-
pants of the KBC study. We defined cases as infants who were admitted with severe pneumo-
nia or lower respiratory tract infection (LRTI) within the first 6 months of life and had a
positive RSV diagnosis by an Immunofluorescent Antibody Test (IFAT; Millipore, USA). Con-
trols were infants who were not admitted to KCH with RSV associated severe pneumonia dur-
ing the follow up period. Exposure to RSV infection among the controls was measured by
screening cord blood and the 3 monthly subsequent samples for RSV IgA ELISA antibodies.
An increase in RSV IgA antibodies detected either in the 3 or 6 month serum sample was used
as a marker of exposure. Cases were matched to controls in a ratio of 1:2 by date of birth
(within 30 days of date of birth) and geographical location. Every participant had a cord blood
sample and two subsequent 3 months follow up blood samples. Continuous surveillance for
RSV in paediatric admissions to KCH with syndromic severe or very severe pneumonia (using
WHO criteria)[23] was in place throughout the KBC study with screening for RSV antigen by
Immunofluorescent Antibody Test (IFAT)[24]. Enhanced detection of RSV cases missed by
using the WHO pneumonia criteria was made by inclusion of children with a clinical admis-
sion diagnosis of LRTI. During the period for RSV surveillance, all paediatric admissions had
blood samples collected for culture to diagnose invasive bacterial pathogens. A computerised
system linking residents of the KHDSS and KCH admissions enabled identification of RSV
positive hospital admission from the KBC.
Furthermore, we investigated whether the level of neutralizing antibodies measured from
RSV A2 infection differs according to the circulating strain within the population. To do this,
an additional subset of 100 cord blood samples was randomly selected from the Kilifi birth
Cohort study regardless of infection status and tested for neutralizing activity to a range of
RSV virus strains.
Ethical Approval
All parents and guardians gave written consent to have their children participate in the KBC
study or paediatric RSV study at KCH and for storage of blood samples for use in future
research. The use of the archived sample set was approved by the KEMRI-Ethical Review
Committee.
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Laboratory Procedures
Cord blood and admission samples collected during the KBC study were immediately taken to
the microbiology laboratory for processing and storage at -80˚C. For this case control study,
archived blood samples were retrieved and assayed for RSV neutralising antibody by a plaque
reduction neutralisation assay. Serum samples were incubated at 56˚C in a water bath for
thirty minutes to inactivate complement cascade proteins; thereafter, plaque reduction neutra-
lisation procedures were conducted as described elsewhere[25]. The dilution (and titre recip-
rocal) of a test serum sample required to induce 50% neutralization of a known titration of
RSV A2 virus was determined using the Spearman Karber method. To account for any signifi-
cant effect of freeze thaw on sample neutralization titres, a validation assay was carried out
where a set of KBC samples previously screened (5 years interval); were retrieved, screened
and the two PRNT titres results compared.
A subset of 100 cord bloods collected over the same time period as for the case-control
study were selected at random, stratified by year, from the KBC archive, as previously
described [16]. These were screened for RSV specific neutralising antibodies by the method
described above using 4 different strains i.e., RSV A2 (Australia, 1961), RSV B860 (Sweden,
1960), RSV A Kilifi (Kenya, 2005) and RSV B Kilifi (Kenya, 2005).
Residues of samples from controls were tested for RSV-specific IgA antibodies by ELISA
using crude virus extract from laboratory adapted RSV A2 culture[26] Specific antibody con-
centrations were recorded as log arbitrary units (AU) as determined by a local standards pro-
cedure[26]. The crude virus RSV lysate preparation was as previously described by Ochola
et al[27].
Statistical analyses
All data analysis was conducted using STATA version 13.1 (College Station, Texas). Labora-
tory data for sample PRNT titres were logarithmically transformed (base 2) and merged with
the KHDSS and clinical data for analyses.
To quantify the level of RSV-specific maternal antibodies at birth that provide infant pro-
tection, mean PRNT titres were computed for cord blood samples. The difference in cord
blood levels between the cases and controls were analysed using a two sample paired t test. For
comparison, a two sample Wilcoxon rank-sum (Mann-Whitney) test was applied to the
log2PRNT titres for cases and controls. Further comparison of the distribution of cord blood
log-transformed PRNT titres between cases and controls was done using reverse cumulative
distribution plots. The absolute reduction in risk of RSV disease per unit increase in cord
blood antibody titres was calculated using modified conditional logistic regression methods
[28]. The estimated rate of decay of RSV specific log2PRNT titres from birth to 6 months of
life was determined by simple linear regression, accounting for clustering of titres for samples
from the same individual using the procedure for Huber-White sandwich estimator. Elimina-
tion of bias on the rate of decay arising from RSV infection was done as previously described
[16]i.e.: the titre of cord, first and second samples for an individual were defined as TC, T1 and
T2, respectively. For individuals with T1TC, all results for that individual were excluded, and
for individuals with T2T1 the result for sample T2 was excluded. In addition, results from
samples collected from cases after an infection was identified were excluded. Comparison of
the estimated rate of decay was conducted using a two sample paired t-test. To further control
for the difference in the estimated rate of decay between cases and controls within a match set,
a linear regression model with an interaction effect between age and case/control was used.
The association between the concentration of maternal antibody titres and gestational age
(measured by clinical evaluation or based on date of last menstruation) and birth weight
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(measured using a weighing scale at birth) was assessed. The odds of severe RSV disease in the
first 6 months of life was determined, adjusting for the potential confounders of prematurity
(i.e. gestational age< 37 weeks) and low birth weight (i.e. <2.5Kg) as categorical variables,
using conditional logistic regression methods[28].
To ascertain exposure among controls, a defined cut off value was computed from the
mean cord blood IgA log AU plus 3 standard deviations. Any of the 3 or 6 months serum sam-
ples with an IgA level above this cut off value were defined as exposed and those below this cut
off as unexposed.
Results
There was a total of 64 participants from the KBC study admitted with laboratory confirmed
RSV-LRTI at the KCH in their first 6 months of life from April 2002 to 2007. Of the 64 individ-
uals, 30(46.9%) participants had a stored cord blood and two 3 monthly follow up blood sam-
ples available. The median (interquartile) age was 3 (1–4) months for the cases at the first RSV
infection. One case had Haemophilus influenzae bacteria isolated from blood culture while the
rest had no significant bacterial pathogen. There was no statistically significant difference in
RSV specific neutralizing titres in the samples screened over time (P = 0.2). The baseline char-
acteristics between cases and controls were similar as shown in Table 1.
Gestational age data was available for 68% [62: 18 cases, 44 controls] of the participants,
while 90% (81: 27 cases, 54 controls) had data on birth weight. The mean birth weight was
3.0Kg (95% CI 2.8–3.2) and 2.8 Kg (95% CI 2.7–3.0) for cases and controls, respectively, while
the mean gestational ages of cases and controls were 38.4 weeks (95% CI 36.9–40.0) and 38.4
weeks (95% CI 37.5–39.3), respectively. Neither birth weight (P = 0.23, t = -1.20) nor gesta-
tional age (P = 0.99, t = 0.006) were statistically significantly different between cases and con-
trols (Table 1).
Testing for RSV specific IgA antibody to ascertain exposure among controls was done on
samples from 53 (88.3%) participants. Out of those tested, 16 (30%) showed evidence of expo-
sure to RSV infection i.e., there was a rise in IgA antibody concentration in the follow up sam-
ples above the defined mean cut off value of 1.7 log AU. A further 30 of the controls showed a
rise in IgA antibody concentration but non above the defined cut off value.
The distribution of log-transformed PRNT titres for cord blood samples for both cases and
controls approximated to normal; with a mean concentration of 10.65 (95% Confidence inter-
val, CI; 10.3–11.0, variance 0.97, median 10.64) for cases and 10.8 (95% CI 10.6–11.1, variance
1.1, median 10.9) for controls.
The difference in mean log2PRNT cord blood neutralising antibody titres between cases
admitted within the first 6 months of life, and including their controls (30 cases and 60 con-
trols) was not statistically significant (P = 0.4, t = -0.78). Similarly, there was not a statistically
significant difference applying the Wilcoxon rank-sum (Mann-Whitney) test (P>0.05). Fur-
ther analysis of the difference in mean log2PRNT cord blood antibody levels between cases
[10.6 (95%CI 10.0–11.1)] and controls [11.1(95%CI 10.6–11.6)], where cases were matched to
controls with confirmed evidence of exposure to RSV infection, showed no evidence of a dif-
ference between the two groups (P = 0.2).
To investigate whether the protective effect of maternal neutralising antibody was related to
age of the individual, and hence time from birth for antibody decay, we did a post-hoc analysis
where the mean neutralising antibody titres in the cord bloods of cases and controls was strati-
fied by the age of cases at which primary infection was identified (i.e. 0–2, 3–5 months) (Fig 1).
No statistically significant difference in antibody levels between cases and controls was identi-
fied for any age category (Table 1). While cases in the 0–2 month age stratum had lower
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log2PRNT titres of RSV neutralising antibody in cord blood 10.3(SD: 1.1) than controls 10.7
(S.D:1.0), the difference was not statistically significant (P = 0.3, t = 1.03).
To further investigate the relationship between level of RSV neutralising antibody in cord
blood between cases and controls, a plot of reverse cumulative distribution of the neutralising
titres was constructed (Fig 2). The graph shows considerable overlap in the distribution of
cord blood RSV antibody titres among infants who became cases and those who did not, and
thus, difficulty in defining a threshold of protection between the two groups.
A plot of the odds of RSV disease against RSV neutralising antibody titres (Fig 3), by which
to guide understanding of the role of antibody concentration in protection against RSV dis-
ease, suggests a decrease in odds of RSV disease with increase in cord blood neutralizing anti-
body titres; with a mean odds of 0.33 (95% CI 0.27–0.44) among all 90 infants.
We estimated a reduction in risk of RSV disease per log2PRNT unit increase in cord blood
antibody titres using conditional logistic regression (though not statistically significant) of
33% (OR = 0.67, 95% CI 0.33–1.38; P = 0.2) and 5% (OR = 0.95, 95%CI 0.45–2.03; P = 0.9)
among infant cases for whom their first RSV disease associated hospitalisation was between
0–2 and 3–5 months, respectively. The overall reduction in risk of RSV disease per log2PRNT
unit increase in cord blood antibody titres in all infants was 21% (OR = 0.79, 95% CI 0.47–
1.31; P = 0.4).
The log2PRNT antibody titre in cord blood showed an increase with increasing gestational
age. However, adjusting for prematurity (i.e. gestational age< 37 weeks) in the conditional
logistic regression analysis did not have an appreciable effect on the outcome (OR = 0.67, 95%
CI 0.19–2.4; P = 0.5).
The estimated rate of decay of RSV specific maternal antibodies (log2PRNT/month) for
participant’s samples collected within 6 months of life was higher in controls -0.55(95% CI:-
0.58 and-0.51) than in cases -0.46(95% CI:-0.53 and-0.38; P = 0.04, t = -2.09) (Fig 4). However,
on estimating the rate of decay using samples collected from participants within the first 3
months of life, the rate of decay between the two groups was not significantly different
(P = 0.1, t = -1.67). Including an interaction effect between age and case or control did not
alter the results of the regression model using Huber sandwich estimator.
Table 1. Characteristics of study participants.
Characteristic Cases (n %) Controls (n %) Total (n %) P value
Sample size 30 60 90
No of samples
cord blood 30 (33.3%) 60 (66.7%) 90 (100%)
3 month 26 (28.9%) 57 (63.3%) 83 (92.2%)
6month 17 (18.9%) 44 (48.9%) 61 (67.8%)
Age in months at first infection for cases only
0–2 13 (23.7%) 26 39
3–5 17 (30.9%) 34 51
Mean birthweight in Kilograms (Kgs) 3(2.8–3.2) 2.8(2.7–3.0) 0.21
Mean gestational age in weeks 38.4(36.9–40.0) 38.4(37.5–39.3) 0.99
Mean (95% CI) cord blood titre in infants admitted<6months [PRNT(log2)] 10.7(10.3–11.0) 10.8(10.6–11.1) 0.4
Mean (95% CI) cord blood titre in infants admitted<3months [PRNT(log2)] 10.3(9.6–10.9) 10.7(10.2–11.1) 0.3
Mean (95% CI) cord blood titre in infants admitted 3–6 months [PRNT(log2)] 11.0(10.6–11.3) 11.0(10.6–11.4) 0.9
Mean (95% CI) decay rates[PRNT(log2)/month6months] -0.46(-.53 -.38) -0.55(-0.58-.51) 0.01
Mean (95% CI) decay rates[PRNT(log2)/month <3months] -0.46(-.57 -.35) -0.55(-.60 -.50) 0.10
doi:10.1371/journal.pone.0166706.t001
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The distribution of cord neutralisation titres for RSV A2 and Kilifi local A strain against
date of collection and overlaying with graphs for annual RSV epidemic in Kilifi for RSV A and
B showed a similar trend indicative of cross protection, i.e., there was an increase in antibody
levels among children born after an epidemic regardless of the RSV strain circulating within
the population (Fig 5). However, the mean log2PRNT titres for A2 RSV strain were signifi-
cantly higher (mean log2PRNT 10.6 [95% Confidence interval (CI) 10.3–10.7]) than those of
the local RSV A circulating strain (mean log2PRNT 9.5 [95% CI 9.3–9.7]; (P<0.001). Similar
results were observed for the comparison between RSV A2 and either the local circulating RSV
B virus which had a mean log2PRNT of 10.3 [95% CI 10.1–10.5]; (P<0.01, t = 2.46) or the
B860 RSV B strain(results not shown).
Discussion
A key target group for RSV disease prevention is young infants under 6 months of age [4, 29],
for whom the risk of severe disease is high. Previous studies have shown evidence that RSV
Fig 1. A box plot of the mean concentration of cord blood titres of cases and controls by age categories. Differences in the mean
concentration of maternally transferred respiratory syncytial virus (RSV) specific antibodies (log2PRNT titres) from cord blood samples (with P values
shown), between cases and controls at age categories in months of first RSV infection; 1–2 and 3–5. Cases were matched to controls in a ratio of 1:2.
P values generated using a two sample paired t-test.
doi:10.1371/journal.pone.0166706.g001
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specific maternal antibodies protect [9–11]. Consequently, maternal vaccination to boost the
level of RSV-specific antibodies in pregnant women to extend the duration of protective anti-
bodies in early infancy has been considered as a realistic approach [8, 9, 30]. However, the
development of an effective vaccine would benefit from definitive information on the protec-
tive levels of RSV-specific neutralising antibodies. We undertook this study to describe the
association between different levels of RSV specific maternal antibodies and the degree of pro-
tection against RSV disease among Kilifi infants.
In this study nested within a birth cohort from coastal Kenya, no significant difference in
the mean concentration of cord RSV specific neutralizing antibodies between cases hospital-
ised with RSV and their controls was identified. Surveillance studies in Kilifi have found a high
proportion of cases of RSV associated severe disease arising in the age group 0–2 months[24];
which is also an age group with highest titres of population level RSV specific maternal anti-
body. Surprisingly, we did not find any strong evidence of protection against severe RSV dis-
ease by neutralizing antibodies in this age group, although, the difference in RSV cord levels
Fig 2. Reverse Cumulative Distribution plots of cord blood titres of cases and controls. The distribution of concentration of maternally
transferred RSV specific antibodies (log2PRNT titres) from cord blood samples of infants born in Kilifi, Kenya. Grey symbols denote cord titres of cases
while black symbols denote cord titres of controls.
doi:10.1371/journal.pone.0166706.g002
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was slightly wider between cases and controls where cases had their first RSV associated hospi-
talization early in life (<3 months).
A similar lack of an overall protective effect by passively acquired maternal RSV neutraliz-
ing antibodies was previously observed by Bulkow in a study conducted among Alaskan native
children [31]. An editorial to this study by Munoz and Glezen, suggested modifications to the
analysis that might reveal a protective effect of maternal antibodies[32]. Among these sugges-
tions were stratification of infants by age of infection, which was undertaken in the present
study but did not reveal a statistically significant association.
To further understand why some infants get severe infection while others do not, we
explored differences in rates of decay of maternally derived RSV specific antibody between
cases and controls. This was based on the premise that infants with maternal antibodies which
decay more rapidly are likely to get infected earlier in life. However, we did not see a differen-
tial in the rate of decay to support this hypothesis. Although we observed a significant differ-
ence in rate of decay between cases and controls within the first 6 months of life, this
difference was unlikely to be of biological significance since the plots appeared similar for the
Fig 3. Relationship between Odds of RSV disease and the levels of Cord blood antibody titres. A scatter plot showing the odds of RSV
associated hospitalization against maternally transferred RSV specific antibodies (log2PRNT titres) from cord blood samples of infants (both cases and
controls) born in Kilifi, Kenya; 2002–2007. Black symbols denote individual cord titres for all 90 infants.
doi:10.1371/journal.pone.0166706.g003
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2 models. This observation is supported by previous analysis of the KBC cohort dataset where
we did not find evidence of variation in the rate of decay with respect to the starting log2PRNT
titre [16].
Transplacental transfer of RSV specific IgG antibodies occurs from the 28th week of gesta-
tion and studies have shown this transfer to be very efficient [13]. In this study, cases and con-
trols were equally distributed in gestational age. We also show that infants born premature
have low levels of RSV specific maternal antibodies but this was unrelated to RSV disease. Nev-
ertheless, it will be important to have alternative RSV disease preventive strategies for high risk
infants especially those born premature, in the event there is a RSV maternal vaccine introduc-
tion to this population.
We observed from the RCD plots considerable overlap in the distribution of log2PRNT
cord titres in those infants who became cases and those who did not. This suggests lack of a
protective effect by RSV specific maternal antibodies in those infants who did not get RSV dis-
ease in this study. However, even though we cannot show a protective effect of RSV specific
Fig 4. The estimated rate of decay of RSV specific antibodies from birth to 6 months of life among cases and controls. The estimated rate of
decay of maternally transferred RSV specific antibodies (log2 transformed PRNT titres) over the first 6 months of life for infants (30 RSV cases and 60
controls) from a birth cohort, Kilifi, Kenya, with best fit linear decay models for samples from cases and controls. Grey symbols denote individual cord
titres of cases while black symbols denote individual cord titres of controls.
doi:10.1371/journal.pone.0166706.g004
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antibody within the range that is transferred naturally, this might not be the case for boosted
levels associated with vaccination. The fact that high levels of intravenous immunoglobulin
(IVIG) have been shown to be highly protective in other studies [33, 34], suggests that, there is
a level of antibody above what is observed in natural exposure that protects.
Despite the overall lack of a protective effect, there is some evidence (though not statistically
significant) of a degree of protection from severe disease conferred by RSV neutralizing anti-
bodies. We estimated a reduction in odds of RSV disease associated hospitalization of 33%
per unit increase in log2PRNT of RSV maternal neutralizing antibodies in age stratum 0–2
months. These results are suggestive that, rather than providing an all or nothing protection,
RSV specific maternal antibodies confer a degree of protection against severe disease that
decreases as the level declines.
Thus in summary, this study shows no effect of maternal antibodies at birth on the risk of
RSV disease, no differential in the rate of decay of RSV specific antibody between cases and
Fig 5. Dynamics of cord titres by time and transmission intensity. The Red diamond symbols denote individual cord titres by date of birth for RSV
A2 strain, Blue diamond symbols denote individual cord titres by date of birth for RSV A Kilifi local strain, Maroon circle markers denote the mean cord
titre by quarter (95% CI denoted by Brown whiskers) for RSV A2 strain, Navy blue circle markers denote the mean cord titre by quarter (95% CI
denoted by Green whiskers) for RSV A Kilifi local strain. The Grey vertical bars (RSVA) and Orange vertical bars (RSV B) show the number of RSV
IFAT positive paediatric severe or very severe pneumonia admissions to Kilifi County Hospital 2002–2005.
doi:10.1371/journal.pone.0166706.g005
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controls, nor a relationship between gestational age and risk of RSV disease. We therefore
hypothesize that, development of RSV disease in this population might be associated with
other underlying factors such as dose of infection, nutritional status, underlying immunity and
environmental factors of which this study did not investigate. Our study also provides support
for a recent conclusion of a randomised, blinded, controlled, dose- ranging study of a RSV
recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age[35] which
found that the immunity developed in response to wild-type RSV infection is insufficient in
quality and quantity to confer high levels of protection. However, it remains plausible that a
high level boosting of maternal antibody with high binding affinity will provide significant
protection to the infant.
There are a number of possible limitations of the study that suggest caution in the interpre-
tation of the results. In particular, limitations that might lead to concluding an absence of an
association between cord RSV neutralising antibody level and protection from severe RSV dis-
ease, even when one existed. The number of cases of children admitted with severe RSV with
cord blood samples was only 30, which diminishes the study power. It is also possible that con-
trols differed from cases in the level and timing of exposure to RSV. We hoped to account for
such exposure bias by closely matching cases to controls by date of birth and geographical loca-
tion. We looked for evidence of exposure in the controls by testing sample residues for RSV
specific IgA ELISA antibodies. A high proportion (87%) showed a rise in titre between sequen-
tial samples, although only for 30% was there a clear seroconversion. Interpretation of these
data is difficult. Low or no rise in titre may not be conclusive of non-exposure given the sam-
pling interval of 3 months which might allow infection, rise and subsequent fall to baseline of
antibody levels, within the time period. Furthermore, maternal antibody might prevent infec-
tion and an acquired immune response. We undertook a sub-analysis of the data using cases
matched to controls with IgA confirmed evidence of exposure which did not give different
results from those observed from the overall analysis.
A further limitation is that we cannot exclude the possibility that the controls had been
admitted with severe RSV to another hospital. However, all members of the KBC from which
the cases and controls arise were recruited at the County hospital (KCH) with three monthly
follow up visits to the KCH clinic, which strongly indicates that KCH would be the hospital to
which sick children from the cohort would present. Of course, the matching of cases and con-
trols may not remove differential exposure to RSV for which we have not accounted, such as
family size, breast feeding, smoke exposure and underlying nutritional status or medical
conditions.
Finally, we note that neutralising antibody titres are not internationally standardised and
hence it is difficult to compare levels identified across different studies. Neutralising antibodies
are directed to both the G and F proteins on the surface of the virus, but the proportion of
each detected may depend upon the cell line chosen for the neutralisation assay [36]. This
could result in underestimation of the protective levels of neutralising antibodies present.
There is also the general question as to whether neutralising antibodies are the main or only
mediator of maternal protection in infants.
Conclusions
In this study in a birth cohort from a coastal Kenya population, there was no significant differ-
ence in cord antibody titres of RSV specific neutralising antibody between severe hospitalized
RSV cases and a set of controls matched on date of birth and location without documented
severe RSV. Based on the small sample size of infants hospitalized within the first 3 months of
life, there is only limited evidence of a protective effect of maternal passively acquired antibody
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over the period 0–2 months of life. There was a suggestion of a relationship between the neu-
tralisation titre at birth and degree of protection from severe RSV disease. It is possible that
factors additional to specific neutralisation antibody levels determine susceptibility to RSV dis-
ease, and that levels of neutralizing antibody beyond the normal range derived from wild type
exposure or of a different composition are required for protection, which it is hoped can be
achieved by a maternal vaccine.
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